FY2018 EPS Estimates for Nevro Corp Increased by William Blair (NVRO)

Nevro Corp (NYSE:NVRO) – Investment analysts at William Blair lifted their FY2018 EPS estimates for shares of Nevro in a note issued to investors on Tuesday, November 6th. William Blair analyst M. Kaczor now anticipates that the medical equipment provider will earn ($1.68) per share for the year, up from their prior estimate of ($2.07). William Blair also issued estimates for Nevro’s Q4 2018 earnings at ($0.36) EPS, Q1 2019 earnings at ($0.58) EPS and FY2019 earnings at ($1.10) EPS.

Nevro (NYSE:NVRO) last posted its quarterly earnings data on Monday, November 5th. The medical equipment provider reported ($0.37) earnings per share for the quarter, missing the consensus estimate of ($0.30) by ($0.07). Nevro had a negative return on equity of 17.89% and a negative net margin of 11.64%. The company had revenue of $95.60 million during the quarter, compared to the consensus estimate of $94.29 million. During the same quarter last year, the firm earned ($0.21) EPS. The business’s revenue for the quarter was up 16.2% on a year-over-year basis.

Other analysts have also recently issued research reports about the stock. Bank of America dropped their target price on shares of Nevro from $102.00 to $77.00 and set a “buy” rating for the company in a research report on Tuesday, July 17th. Canaccord Genuity dropped their target price on shares of Nevro from $102.00 to $83.00 and set a “buy” rating for the company in a research report on Monday, July 16th. Morgan Stanley dropped their target price on shares of Nevro from $88.00 to $65.00 and set an “equal weight” rating for the company in a research report on Tuesday, July 17th. Zacks Investment Research upgraded shares of Nevro from a “sell” rating to a “hold” rating in a research report on Tuesday, September 18th. Finally, Wells Fargo & Co dropped their target price on shares of Nevro from $62.00 to $50.00 and set a “market perform” rating for the company in a research report on Tuesday. Three research analysts have rated the stock with a sell rating, six have given a hold rating and three have issued a buy rating to the stock. Nevro has a consensus rating of “Hold” and a consensus target price of $64.11.

Shares of Nevro stock opened at $41.92 on Thursday. The firm has a market cap of $1.15 billion, a price-to-earnings ratio of -33.54 and a beta of -0.29. Nevro has a 52 week low of $35.41 and a 52 week high of $94.34. The company has a debt-to-equity ratio of 0.62, a current ratio of 8.05 and a quick ratio of 6.29.

Several hedge funds have recently made changes to their positions in the company. Xact Kapitalforvaltning AB grew its holdings in shares of Nevro by 23.1% in the 2nd quarter. Xact Kapitalforvaltning AB now owns 4,258 shares of the medical equipment provider’s stock valued at $340,000 after buying an additional 800 shares during the period. Rhumbline Advisers grew its holdings in shares of Nevro by 3.1% in the 2nd quarter. Rhumbline Advisers now owns 28,525 shares of the medical equipment provider’s stock valued at $2,278,000 after buying an additional 856 shares during the period. Ladenburg Thalmann Financial Services Inc. grew its holdings in shares of Nevro by 69.7% in the 1st quarter. Ladenburg Thalmann Financial Services Inc. now owns 2,432 shares of the medical equipment provider’s stock valued at $210,000 after buying an additional 999 shares during the period. UBS Group AG grew its holdings in shares of Nevro by 38.0% in the 1st quarter. UBS Group AG now owns 5,479 shares of the medical equipment provider’s stock valued at $474,000 after buying an additional 1,509 shares during the period. Finally, Gradient Investments LLC grew its holdings in shares of Nevro by 38.5% in the 2nd quarter. Gradient Investments LLC now owns 9,195 shares of the medical equipment provider’s stock valued at $734,000 after buying an additional 2,555 shares during the period.

About Nevro

Nevro Corp., a medical device company, provides products for the patients suffering from chronic pain in the United States and internationally. The company develops and commercializes the Senza spinal cord stimulation system, an evidence-based neuromodulation platform for the treatment of chronic pain.

Further Reading: The Discount Rate – What You Need to Know

Earnings History and Estimates for Nevro (NYSE:NVRO)

Receive News & Ratings for Nevro Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nevro and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply